the safety and efficacy of mb-106 for the treatment of waldenström’s macroglobulinemia
Published 1 year ago • 270 plays • Length 1:12Download video MP4
Download video MP3
Similar videos
-
1:19
safety and efficacy of mb-106 for the treatment of r/r fl
-
1:24
the long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated wm
-
2:33
the effect of lymphodepleting agents on rate and severity of toxicities following car-t infusion
-
1:27
preventing and monitoring cardiotoxicities associated with treatment for hematologic malignancies
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
4:04
results of phase ii trial to assess the efficacy and safety of idelalisib
-
1:11
personalized risk assessment for transplantation in primary immunodeficiency disorders
-
1:54:36
saeindia functional safety - automotive functional safety iso 26262 – principles & practices-1
-
35:20
webinar - safety cases and verification - identifying and managing safety critical equipment
-
59:34
oshc ( mandatory 8-hour safety seminar)
-
55:41
promed - webinar: safety critical communications protocols
-
3:17
estimating transfusion-related medical costs & time burden in patients with mf in simplify-1
-
0:58
itacitinib for the prevention of immune effector cell therapy–associated crs
-
2:53
long-term safety of momelotinib in myelofibrosis: pooled data from three phase iii randomized trials
-
2:41
an overview of the latest advances in hematology
-
1:28
momelotinib in 2024: how should this agent be used in mf with anemia?
-
47:49
patient blood management: why, what and now: aryeh shander, md, fccm, fccp, 2016
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
44:06
oncological emergencies: acute oncology
-
2:28
checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to allosct for hl
-
1:30
xport-mf-044 trial: evaluating selinexor in jak inhibitor-naïve mf and moderate thrombocytopenia